Genmab A (GMAB) Income from Continuing Operations (2018 - 2026)
Genmab A (GMAB) posted Income from Continuing Operations of 74000000.0 for Q1 2026, down 93.56% on a QoQ basis from 1149000000.0 in Q3 2025, and down 69.67% year-over-year from 244000000.0 in Q1 2025.
Genmab A (GMAB) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Genmab A's Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 74000000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 69.67% year-over-year to 74000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2134000000.0 (down 27.29% YoY) and the FY2025 annual result came in at 963000000.0, up 34.5% from the prior year.
- Income from Continuing Operations was 74000000.0 for Q1 2026 at Genmab A, down from 1149000000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1326000000.0 in Q4 2024 and bottomed at 74000000.0 in Q1 2026.
- A 3-year average of 634250000.0 and a median of 611500000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations jumped 42.03% — and 2026, when it plunged 69.67%.
- Genmab A's Income from Continuing Operations stood at 1326000000.0 in 2024, then dropped by 13.35% to 1149000000.0 in 2025, then plunged by 93.56% to 74000000.0 in 2026.
- Business Quant data shows GMAB's Income from Continuing Operations at 74000000.0 in Q1 2026, 1149000000.0 in Q3 2025, and 667000000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Genmab A | 1.89 Bn | 366.92 Mn | 831.00 Mn | 74.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.00 Mn |
| Sep 30, 2025 | 1.15 Bn |
| Jun 30, 2025 | 667.00 Mn |
| Mar 31, 2025 | 244.00 Mn |
| Dec 31, 2024 | 1.33 Bn |
| Sep 30, 2024 | 809.00 Mn |
| Jun 30, 2024 | 556.00 Mn |
| Mar 31, 2024 | 249.00 Mn |
| Sep 30, 2020 | 671.00 |
| Dec 31, 2019 | 699.00 |
| Sep 30, 2019 | 699.28 Mn |
| Dec 31, 2018 | 230.60 Mn |